INOZYME PHARMA, INC. Patent Applications Rejected
3 applications abandoned without a patent; the status gives the reason, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.
- 2024-10-02: Application 18904634; Invention METHODS OF IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING A RECOMBINANT ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE (NPP1); Applicant Inozyme Pharma, Inc.; Status Abandoned -- Incomplete Application (Pre-examination).
- 2022-08-11: Application 17819065; Invention NPP1 FUSION PROTEINS; Applicant Inozyme Pharma, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
- 2020-11-25: Application 17105245; Invention NPP1 FUSION PROTEINS; Applicant Inozyme Pharma, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
| Filed | Application | Invention | Applicant | Status | Published as | Inventor name | Inventor country | Examiner |
|---|---|---|---|---|---|---|---|---|
| 2024-10-02 | 18904634 | METHODS OF IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING A RECOMBINANT ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE (NPP1) | Inozyme Pharma, Inc. | Abandoned -- Incomplete Application (Pre-examination) | US20250019677A1 | Ms. Tayeba Khan Mr. Andre Marozsan Ms. Kim Lynette Askew | United States United States United States | |
| 2022-08-11 | 17819065 | NPP1 FUSION PROTEINS | Inozyme Pharma, Inc. | Abandoned -- Failure to Respond to an Office Action | US20230129977A1 | Anthony Quinn Alex J. Harvey Zhinan Xia | United States United States United States | EPSTEIN, TODD MATTHEW |
| 2020-11-25 | 17105245 | NPP1 FUSION PROTEINS | Inozyme Pharma, Inc. | Abandoned -- Failure to Respond to an Office Action | US20210301268A1 | Anthony Quinn Alex J. Harvey Zhinan Xia | United States United States United States | EPSTEIN, TODD MATTHEW |